Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Zaidi H, Pendleton C, McGirt MJ, Grossman R, Weingart JD, et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res. 2011;33:759–64.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110:583–8.
   PubMed Web of Science ®Google Scholar
• McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO. Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis. 2003;36:759–65.
   PubMed Web of Science ®Google Scholar
• Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery. 1999;45:17–22.
   PubMed Web of Science ®Google Scholar
• Samis Zella MA, Wallocha M, Slotty PJ, Isik G, Hanggi D, Schroeteler J, et al. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. Acta Neurochir (Wien). 2014;156:313–23.
   PubMed Web of Science ®Google Scholar
• Brell M, Ibanez J, Caral L, Ferrer E. Factors influencing surgical complications of intra-axial brain tumours. Acta Neurochir (Wien). 2000;142:739–50.
   PubMed Web of Science ®Google Scholar
• Chang SM, Parney IF, McDermott M, Barker FG 2nd, Schmidt MH, Huang W, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg. 2003;98:1175–81.
   PubMed Web of Science ®Google Scholar
• Gulati S, Jakola AS, Nerland US, Weber C, Solheim O. The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg. 2011;76:572–9.
   PubMed Web of Science ®Google Scholar
• Rabadan AT, Hernandez D, Eleta M, Pietrani M, Baccanelli M, Christiansen S, et al. Factors related to surgical complications and their impact on the functional status in 236 open surgeries for malignant tumors in a Latino-American hospital. Surg Neurol. 2007;68:412–20, [discussion 420].
   PubMed Web of Science ®Google Scholar
• Spratt DE, Folkert M, Zumsteg ZS, Chan TA, Beal K, Gutin PH, et al. Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. J Neurooncol. 2014;116:357–63.
   PubMed Web of Science ®Google Scholar
• Nuno M, Ly D, Ortega A, Sarmiento JM, Mukherjee D, Black KL, et al. Does 30-day readmission affect long-term outcome among glioblastoma patients? Neurosurgery. 2014;74:196–204.
   Google Scholar
• Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999.Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20:250–78, [quiz 279–80].
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16:113–22.
   PubMed Web of Science ®Google Scholar
• Ukawa N, Tanaka M, Morishima T, Imanaka Y. Organizational culture affecting quality of care: guideline adherence in perioperative antibiotic use. Int J Qual Health Care. 2014;27(1):37–45.
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report. 32. 2004;. data summary from January 1992 through June 2004, issued October 2004.Am J Infect Control..
   Google Scholar
• Chaichana KL, Pendleton C, Chambless L, Camara-Quintana J, Nathan JK, Hassam-Malani L, et al. Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. J Clin Neurosci. 2013;20:1422–6.
   PubMed Web of Science ®Google Scholar
• Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008;24:3239–57.
   PubMed Web of Science ®Google Scholar
• Bock HC, Puchner MJ, Lohmann F, Schutze M, Koll S, Ketter R, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev. 2010;33:441–9.
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008–12.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79–88.
   PubMed Web of Science ®Google Scholar
• Noel G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys. 2012;82:749–55.
   PubMed Web of Science ®Google Scholar
• Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol. 1995;26:111–23.
   PubMed Web of Science ®Google Scholar
• Korinek AM, Golmard JL, Elcheick A, Bismuth R, van Effenterre R, Coriat P, et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg. 2005;19:155–62.
   PubMed Web of Science ®Google Scholar
• Korinek AM. Risk factors for neurosurgical site infections after craniotomy: a prospective multicenter study of 2944 patients. The French Study Group of Neurosurgical Infections, the SEHP, and the C-CLIN Paris-Nord. Service Epidemiologie Hygiene et Prevention. Neurosurgery. 1997;41:1073–9.
   PubMed Web of Science ®Google Scholar
• Tenney JH, Vlahov D, Salcman M, Ducker TB. Wide variation in risk of wound infection following clean neurosurgery. Implications for perioperative antibiotic prophylaxis. J Neurosurg. 1985;62:243–7.
   PubMed Web of Science ®Google Scholar
• Chaichana KL, McGirt MJ, Woodworth GF, Datoo G, Tamargo RJ, Weingart J, et al. Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. Neurol Res. 2010;32:442–8.
   PubMed Web of Science ®Google Scholar